Here are 1-3 brief analogies to describe Quanterix:

• They're like Illumina, but for ultra-sensitive protein detection and biomarker analysis instead of DNA sequencing.
• Imagine a specialized Thermo Fisher Scientific that focuses entirely on developing ultra-sensitive instruments and assays to detect minute amounts of disease-related biomarkers.

• HD-X Instrument: A sensitive, automated platform for multiplex protein detection.
• SR-X Instrument: An instrument that applies Simoa detection technology for various applications, including direct nucleic acid detection.
• SP-X Instrument: A platform based on Simoa planar array technology for measuring multiplex chemiluminescent immunoassays.
• Assay Kits & Consumables: Complementary kits, reagents, and other consumables essential for use with their immunoassay platforms.
• Contract Research Services: Services encompassing sample testing, homebrew assay development, and custom development to support life sciences research.

Major Customers of Quanterix (QTRX)

Based on the provided description, Quanterix sells its products and services primarily to organizations within the life science research sector. While specific customer names are not listed in the background information, its major customer categories include:

• Academic and Governmental Research Institutions: This category encompasses laboratories associated with universities, colleges, and various governmental research agencies.
• Pharmaceutical and Biotechnology Companies: These are companies involved in the research, development, and manufacturing of drugs and biological products.
• Contract Research Organizations (CROs): These companies provide research services on a contract basis to the pharmaceutical, biotechnology, and medical device industries.

Everett Cunningham, President and Chief Executive Officer

Everett Cunningham was appointed President and Chief Executive Officer of Quanterix, effective January 19, 2026. Prior to joining Quanterix, he served as Chief Commercial Officer at Illumina since June 2024, where he was responsible for the company's global commercial strategy and execution. During his tenure at Illumina, he helped implement a redesigned commercial operating model. Before Illumina, Mr. Cunningham was Chief Commercial Officer at Exact Sciences, where he led marketing, sales, and customer service for their cancer screening and precision oncology diagnostics portfolio. He also held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer.

Vandana Sriram, Chief Financial Officer

Vandana Sriram is the Chief Financial Officer of Quanterix. Her insider holdings at Quanterix were reported in February 2026.

Here are the key risks to Quanterix's business:

1. Reliance on Single-Source Contract Manufacturers: Quanterix is significantly exposed to supply chain risk due to its dependence on single-source contract manufacturers, including STRATEC, Paramit, and Columbia Tech, for the production of its critical Simoa HD-X, SR-X, PhenoCycler, and PhenoImager instruments. Any failure, delay, or quantity shortfall from these manufacturers or their own limited suppliers could materially disrupt instrument supply, adversely affecting Quanterix's business, financial condition, operating results, and reputation.
2. Market Headwinds and Profitability Challenges: The company faces ongoing market headwinds, including reduced funding in academic research and biopharma spending. This has contributed to revised revenue guidance and persistent net losses. While Quanterix aims to achieve cash flow breakeven in the second half of 2026, the path to sustained profitability remains uncertain, with the company recording significant losses in recent periods.
3. Risk of Technological Obsolescence and Intense Competition: Operating in the rapidly innovating biotechnology sector, Quanterix faces the constant threat that its current Simoa technologies could become obsolete. Competitors may introduce more efficient or cost-effective diagnostic technologies, necessitating continuous investment in research and development to maintain its competitive edge.

Quanterix Corporation (QTRX) is poised for future revenue growth over the next two to three years, driven by its strategic focus on key areas within precision health and life sciences research. The company's anticipated growth drivers include the commercialization of its Alzheimer's diagnostics, sustained expansion in consumables and assay sales, the successful integration of Akoya Biosciences and corresponding market penetration in spatial biology, and the broader adoption of its ultra-sensitive Simoa and spatial biology platforms.

One primary driver is the **advancement and commercialization of Alzheimer's diagnostics**. Quanterix is actively pursuing FDA approval for its Alzheimer's diagnostics, with significant growth targeted for 2027. The company reached key milestones in late 2025 and early 2026, including the Centers for Medicare & Medicaid Services (CMS) approving a reimbursement rate of $897 for its LucentAD Complete test, and the submission of a 510(k) premarket notification to the FDA for the same test in January 2026.

Secondly, **continued growth in consumables and assay sales** is expected to fuel revenue. Consumables demonstrated strong performance in Q4 2025, and Quanterix anticipates this trend to persist. By the end of 2025, recurring revenue, largely from consumables, constituted approximately 75% of the total revenue, indicating a stable and growing base.

A third significant driver is the **strategic integration of Akoya Biosciences and expansion into spatial biology**. The acquisition of Akoya Biosciences expanded Quanterix's portfolio, creating an integrated platform for biomarker analysis across both blood (Simoa) and tissue (spatial biology). The company is on track to realize planned cost synergies from this integration, with the remaining synergies expected to be captured by the end of Q1 2026. This expanded offering allows Quanterix to address new markets and applications.

Lastly, **broadening adoption of Simoa and spatial biology platforms** is critical for future revenue. Quanterix has seen accelerating scientific validation and publication activity, with cumulative publications reaching over 6,300 by year-end 2025, reflecting increasing researcher adoption of both its Simoa and spatial biology technologies. The company is focused on deepening customer and partner relationships, which is expected to drive further utilization and placement of its instruments.

Share Repurchases

• Quanterix repurchased $1.45 million in common stock in 2025.
• The company repurchased $2.61 million in common stock in 2024.
• In 2023, share repurchases amounted to $0.2 million.

Share Issuance

• In February 2021, Quanterix completed a public offering of 4,107,142 shares of common stock at $70.00 per share, generating approximately $287.5 million in gross proceeds.
• As part of the Akoya Biosciences acquisition in July 2025, Quanterix offered 7.8 million shares to Akoya's investors.
• Proceeds from common stock issued under stock plans were $0.74 million in 2025, a decrease from $3.07 million in 2024, and $2.89 million in 2023.

Outbound Investments

• Quanterix acquired Akoya Biosciences in July 2025, an investment that included 7.8 million shares offered and $20 million paid, aiming to add integrated spatial biology capabilities and diversify revenue streams.
• In January 2025, Quanterix acquired Emission, Inc. for an upfront payment of $10.0 million, with potential additional payments of $10.0 million upon technical milestones and up to $50.0 million in earnout payments through December 31, 2029.
• The company has implemented $74 million of an $85 million cost-synergy target related to the Akoya acquisition by the end of 2025, with full realization expected by the first quarter of 2026.

Capital Expenditures

• Quanterix's capital expenditures were $2.61 million in 2025, $3.37 million in 2024, $3.84 million in 2023, $11.61 million in 2022, and $13.68 million in 2021.
• Capital expenditures are primarily focused on purchasing equipment to support the company's infrastructure and enhancing product offerings, including the planned launch of the next-generation Simoa ONE instrument by the end of 2025.
• The company expects to incur additional capital expenditures in future periods to support these efforts and aims to achieve cash flow breakeven in the second half of 2026.